AI in Drug Discovery Market
完整報告名稱與涵蓋範圍
AI in Drug Discovery Market by Process (Target, Lead), Use Case (Repurposing, DE Novo Drug Design [Vaccine] Optimization, Disease Understanding, PK/PD), Therapy (Cancer, CNS), Tool (DL [CNN, GAN]), End User - Global Forecast to 2031
報告摘要
The AI in drug discovery market is anticipated to grow from USD 5.09 billion in 2026 to USD 17.56 billion by 2031, at a CAGR of 28.1% during the forecast period. The market is driven by the increasing adoption of AI to improve R&D productivity, expanding use of multimodal biological datasets, and growing investments in precision medicine and computational drug discovery. According to a 2025 review published in Drug Discovery Today, declining pharmaceutical R&D productivity continues to reshape innovation strategies across the biopharmaceutical industry, prompting companies to increasingly adopt AI-driven platforms to improve research efficiency and accelerate drug discovery. However, challenges related to data quality, model validation, regulatory uncertainty, and integration with existing pharmaceutical R&D workflows continue to influence the pace of market adoption.
Machine learning to be the fastest-growing AI tool segment between 2026 and 2031
By AI tool, the machine learning segment is expected to register the fastest growth during the forecast period as pharmaceutical companies increasingly leverage predictive algorithms to improve decision-making across the drug discovery workflow. Machine learning enables rapid analysis of complex biological, chemical, and clinical datasets, significantly enhancing target identification, hit prioritization, molecular property prediction, and lead optimization. Continuous advancements in deep learning, graph neural networks, and generative AI have further expanded the application of machine learning across small molecule discovery, biologics development, and precision medicine research. Reflecting this trend, in March 2026, NVIDIA expanded its BioNeMo platform with next-generation foundation models and agentic AI capabilities to accelerate biomolecular research and molecular design. As pharmaceutical companies continue to prioritize faster drug development and improved R&D efficiency, machine learning is expected to remain the fastest-growing technology segment in the AI in drug discovery market.
Oncology segment accounted for the largest share of the AI in drug discovery market in 2025
By therapeutic area, the oncology segment accounted for the largest share of the AI in drug discovery market in 2025 due to the high global cancer burden, extensive oncology research pipelines, and increasing demand for precision therapeutics. According to the International Agency for Research on Cancer (IARC), global cancer incidence is projected to increase from 20.6 million new cases in 2024 to 34.4 million by 2050, highlighting the growing need for innovative technologies that can accelerate oncology drug discovery. AI is widely adopted to identify novel therapeutic targets, predict biomarkers, optimize patient stratification, and accelerate the discovery of targeted therapies and immuno-oncology drugs. The availability of large genomic, transcriptomic, proteomic, and clinical datasets has made oncology one of the most data-rich therapeutic areas, enabling AI models to generate more accurate and clinically relevant insights. Pharmaceutical companies continue to prioritize oncology within their R&D portfolios due to its significant commercial potential and the growing demand for personalized cancer therapies. Increasing collaborations between AI companies and oncology-focused biopharmaceutical organizations are further accelerating innovation and reinforcing oncology’s leading position in the AI in drug discovery market.
Europe to exhibit the second-highest CAGR during the forecast period
Europe is expected to register the second-highest growth rate during the forecast period, driven by increasing investments in pharmaceutical innovation, expanding adoption of AI across biomedical research, and a strong regulatory framework supporting trustworthy AI. The region is home to leading pharmaceutical companies, research institutions, and AI-native biotechnology firms that are accelerating the integration of AI into target discovery, molecular design, and precision medicine. The implementation of the European Health Data Space (EHDS) and the EU AI Act is expected to facilitate secure cross-border access to health data while establishing harmonized governance for AI applications in life sciences. In parallel, the proposed Cloud and AI Development Act (CADA) aims to strengthen Europe’s cloud and AI infrastructure by expanding sovereign computing capacity, improving access to high-performance computing resources, and supporting the development of AI innovation across strategic sectors, including healthcare and life sciences. In addition, collaborative programs such as the Innovative Health Initiative (IHI) continue to fund AI-enabled drug discovery projects, including LIGAND-AI, to accelerate therapeutic research through high-quality biological datasets and advanced AI models. Collectively, these initiatives are expected to reinforce its position as the second-fastest-growing regional market for AI in drug discovery.
The breakdown of primary participants is as mentioned below:
• By Company Type - Tier 1: 32%, Tier 2: 44%, and Tier 3: 24%
• By Designation - Directors: 30%, Managers: 34%, and Others: 36%
• By Region - North America: 40%, Europe: 28%, Asia Pacific: 20%, Latin America: 7%, and Middle East & Africa: 5%
Key Players
The key players operating in the AI in drug discovery market include NVIDIA Corporation (US), Schrödinger, Inc. (US), Recursion (US), Insilico Medicine (US), Google (US), Microsoft Corporation (US), Tempus AI, Inc. (US), Illumina, Inc. (US), XtalPi Inc. (China), and Iktos (France). These companies have adopted strategies such as strategic partnerships, collaborations, product launches, platform enhancements, investments in foundation models and generative AI, mergers and acquisitions, and geographic expansion to strengthen their market presence in the market.
Research Coverage
The report analyzes the AI in drug discovery market. It aims to estimate the market size and future growth potential of various market segments based on process, use case, therapeutic area, player type, AI tool, deployment model, end user, and region. The report also analyzes factors such as drivers, restraints, opportunities, and challenges influencing market growth. It evaluates opportunities across the AI-driven drug discovery ecosystem and assesses the competitive landscape for key stakeholders. The report further analyzes micro markets with respect to their growth trends, prospects, and contributions to the overall AI in drug discovery market. It forecasts market revenue across major regions and provides a comprehensive competitive analysis of leading market participants, including their company profiles, product portfolios, recent developments, and key growth strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the following strategies to strengthen their positions in the market.
This report provides insights on:
• Analysis of key drivers (Rising need to reduce time and cost of drug discovery and development, Growing utilization of AI to predict drug-target interactions for cancer therapy), restraints (Shortage of AI workforce and regulatory frameworks for AI-enabled drug discovery, Increasing AI compute infrastructure costs amid global HBM/DRAM/NAND shortage), opportunities (Accelerating biotech drug discovery, AI-driven single-cell analysis for biomarker and disease-subtype identification), and challenges (Limited availability of high-quality training datasets, Limited real-world clinical validation of AI-derived drug candidates) are factors contributing the growth of the AI in drug discovery market
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and software launches in the AI in drug discovery market
• Market Development: Comprehensive information on high-growth market segments across process, use case, therapeutic area, player type, AI tool, deployment model, end user, and region
• Market Diversification: Exhaustive information on product portfolios, technology advancements, expanding geographic presence, strategic collaborations, investments, and recent developments in the AI in drug discovery market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, technology capabilities, and competitive strengths of leading players in the global AI in drug discovery market, including NVIDIA Corporation (US), Schrödinger, Inc. (US), Recursion (US), Insilico Medicine (US), Google (US), Microsoft Corporation (US), Tempus AI, Inc. (US), Illumina, Inc. (US), XtalPi Inc. (China), and other major market participants
授權報價
| Single User Licence | $4,950 USD |
| Multi User Licence | $6,650 USD |
| Corporate User Licence | $8,150 USD |
| Global User Licence | $10,000 USD |
目錄 Table of Contents
1 INTRODUCTION 49
1.1 STUDY OBJECTIVES 49
1.2 MARKET DEFINITION 49
1.3 MARKET SCOPE 50
1.3.1 MARKET SEGMENTATION 50
1.3.2 REGIONAL SCOPE 51
1.3.3 INCLUSIONS & EXCLUSIONS 51
1.3.4 YEARS CONSIDERED 53
1.4 CURRENCY CONSIDERED 54
1.5 LIMITATIONS 54
1.6 STAKEHOLDERS 55
1.7 SUMMARY OF CHANGES 56
2 EXECUTIVE SUMMARY 57
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 57
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 59
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 60
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 61
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 62
3 PREMIUM INSIGHTS 64
3.1 AI IN DRUG DISCOVERY MARKET OVERVIEW 64
3.2 AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT & COUNTRY 65
3.3 AI IN DRUG DISCOVERY MARKET: GEOGRAPHIC SNAPSHOT 66
4 MARKET OVERVIEW 67
4.1 INTRODUCTION 67
4.2 MARKET DYNAMICS 68
4.2.1 DRIVERS 68
4.2.1.1 Increasing number of cross-industry collaborations and partnerships 68
4.2.1.2 Rising need to reduce time and cost of drug discovery and development 70
4.2.1.3 Patent expiry of drugs and need for effective new leads 71
4.2.1.4 Growing utilization of AI to predict drug-target interactions for
cancer therapy 71
4.2.1.5 Integration of AI-assisted multiomics in drug discovery 72
4.2.1.6 Growing focus on rare disease treatments for orphan
drug development 73
4.2.2 RESTRAINTS 73
4.2.2.1 Shortage of AI workforce and ambiguous regulatory guidelines for medical software 73
4.2.3 OPPORTUNITIES 74
4.2.3.1 Leveraging AI for accelerated biotech drug discovery 74
4.2.3.2 Increased focus on drug discovery in emerging economies 75
4.2.3.3 Focus on developing human-aware AI systems 76
4.2.3.4 Growing use of AI in single-cell analysis 76
4.2.3.5 Easy identification of biomarker and disease subtypes from
single-cell data 77
4.2.3.6 High demand for precision and personalized medicines 78
4.2.4 CHALLENGES 79
4.2.4.1 Limited availability of quality data sets 79
4.2.4.2 Lack of advanced AI tools and training data sets 79
4.2.4.3 Computational constraints of advanced AI models 80
4.2.4.4 Lack of high-quality data sets for model training 80
4.3 UNMET NEEDS AND WHITE SPACES 81
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 82
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 83
5 INDUSTRY TRENDS 84
5.1 PORTER’S FIVE FORCES ANALYSIS 84
5.1.1 BARGAINING POWER OF SUPPLIERS 85
5.1.2 BARGAINING POWER OF BUYERS 85
5.1.3 THREAT OF SUBSTITUTES 85
5.1.4 THREAT OF NEW ENTRANTS 85
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 85
5.2 MACROECONOMIC INDICATORS 86
5.2.1 INTRODUCTION 86
5.2.2 GDP TRENDS AND FORECAST 86
5.2.3 GLOBAL PHARMACEUTICAL R&D EXPENDITURE AND PRODUCTIVITY TRENDS 87
5.3 VALUE CHAIN ANALYSIS 88
5.3.1 RESEARCH, DATA GENERATION, AND SCIENTIFIC INPUTS 89
5.3.2 DATA ENGINEERING & AI INFRASTRUCTURE 89
5.3.3 AI MODEL & PLATFORM DEVELOPMENT 90
5.3.4 AI WORKFLOW INTEGRATION & DEPLOYMENT 90
5.3.5 DRUG DISCOVERY SERVICES & EXPERIMENTAL EXECUTION 90
5.3.6 VALIDATION, LAB-IN-THE-LOOP, AND CONTINUOUS OPTIMIZATION 90
5.4 ECOSYSTEM ANALYSIS 91
5.5 PRICING ANALYSIS 92
5.5.1 INDICATIVE PRICE FOR AI IN DRUG DISCOVERY PLATFORMS, BY KEY PLAYERS (2025) 93
5.5.2 INDICATIVE PRICE FOR AI IN DRUG DISCOVERY SOFTWARE AND SERVICES, BY REGION (2025) 94
5.6 KEY CONFERENCES AND EVENTS, 2026–2027 96
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 97
5.8 INVESTMENT AND FUNDING SCENARIO 98
5.9 CASE STUDY ANALYSIS 99
5.10 IMPACT OF 2025 US TARIFF – AI IN DRUG DISCOVERY MARKET 101
5.10.1 INTRODUCTION 101
5.10.2 KEY TARIFF RATES 101
5.10.3 PRICE IMPACT ANALYSIS 102
5.10.4 IMPACT ON COUNTRY/REGION 102
5.10.4.1 US 102
5.10.4.2 Europe 103
5.10.4.3 Asia-Pacific 103
5.10.5 IMPACT ON END-USE INDUSTRIES 103
5.10.5.1 Pharmaceutical companies 103
5.10.5.2 Biotechnology companies 103
5.10.5.3 CROs and CDMOs 104
5.10.5.4 Academic and research users 104
5.10.5.5 Other end users 104
6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL,
AND AI ADOPTION 105
6.1 KEY EMERGING TECHNOLOGIES 105
6.1.1 GENERATIVE AND AGENTIC AI FOR DRUG DISCOVERY 105
6.1.2 MULTIMODAL AI AND FOUNDATION MODELS 105
6.1.3 AI-ENABLED AUTONOMOUS LABORATORIES 106
6.2 COMPLEMENTARY TECHNOLOGIES 106
6.2.1 CLOUD COMPUTING AND HIGH-PERFORMANCE COMPUTING 106
6.2.2 HIGH-THROUGHPUT SCREENING AND LABORATORY AUTOMATION 106
6.3 ADJACENT TECHNOLOGIES 106
6.3.1 MULTIOMICS AND SINGLE-CELL TECHNOLOGIES 107
6.3.2 DIGITAL TWINS AND IN-SILICO CLINICAL TECHNOLOGIES 107
6.4 TECHNOLOGY/PRODUCT ROADMAP 107
6.5 PATENT ANALYSIS 108
6.5.1 PATENT PUBLICATION TRENDS FOR AI IN DRUG DISCOVERY MARKET 108
6.5.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 109
6.6 FUTURE APPLICATIONS 112
6.6.1 AUTONOMOUS END-TO-END DRUG DISCOVERY 112
6.6.2 AI-DRIVEN PRECISION DRUG DISCOVERY AND PATIENT-SPECIFIC THERAPEUTICS 113
6.6.3 AI-ENABLED DIGITAL AND VIRTUAL DRUG DEVELOPMENT 113
7 REGULATORY LANDSCAPE 114
7.1 REGIONAL REGULATIONS AND COMPLIANCE 114
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, & OTHER ORGANIZATIONS 115
7.1.2 REGULATORY FRAMEWORK 121
7.1.2.1 North America 121
7.1.2.2 Europe 121
7.1.2.3 Asia Pacific 123
7.1.2.4 Latin America 125
7.1.2.5 Middle East & Africa 126
7.1.3 INDUSTRY STANDARDS 128
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 129
8.1 INTRODUCTION 129
8.2 DECISION-MAKING PROCESS 129
8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 130
8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 130
8.3.2 BUYING CRITERIA 131
8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES 132
8.5 UNMET NEEDS FROM VARIOUS END USERS 133
8.5.1 UNMET NEEDS 133
8.5.2 END USER EXPECTATIONS 134
8.6 MARKET PROFITABILITY 135
9 AI IN DRUG DISCOVERY MARKET, BY PROCESS 136
9.1 INTRODUCTION 137
9.2 TARGET IDENTIFICATION & SELECTION 137
9.2.1 INCREASED DEMAND FOR PERSONALIZED MEDICINES AND HIGH INVESTMENT IN PHARMACEUTICAL R&D TO FUEL MARKET GROWTH 137
9.3 TARGET VALIDATION 139
9.3.1 RISING EMPHASIS ON AVOIDING LATE-STAGE FAILURE IN DRUG DISCOVERY TO BOOST MARKET GROWTH 139
9.4 HIT IDENTIFICATION & PRIORITIZATION 140
9.4.1 NEED FOR LARGE-SCALE DATA ANALYSIS TO DRIVE ADOPTION 140
9.5 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION 141
9.5.1 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION TO IMPROVE NEW DRUG POTENCY WITHOUT INCREASING LIPOPHILICITY 141
9.6 LEAD OPTIMIZATION 142
9.6.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST
MARKET GROWTH 142
9.7 CANDIDATE SELECTION & VALIDATION 144
9.7.1 HIGH POSSIBILITY OF CLINICAL DRUG FAILURE TO SPUR ADOPTION OF CANDIDATE VALIDATION SERVICES 144
10 AI IN DRUG DISCOVERY MARKET, BY AI TOOL 146
10.1 INTRODUCTION 147
10.2 MACHINE LEARNING 148
10.2.1 INCREASING AVAILABILITY OF COMPLEX BIOLOGICAL AND CHEMICAL DATASETS DRIVES ADOPTION 148
10.2.2 DEEP LEARNING 150
10.2.2.1 Ability to capture complex nonlinear relationships across multimodal biological and molecular data – key driver 150
10.2.2.2 Transformer-based architectures 152
10.2.2.2.1 Growing volumes of sequential, multimodal, and unstructured scientific data drives market 152
10.2.2.3 Graph neural networks (GNN) 153
10.2.2.3.1 Need to understand molecular structure and complex biological relationships supports GNN adoption 153
10.2.2.4 Convolutional neural networks (CNN) 154
10.2.2.4.1 Expansion of image-based and 3D structural analysis boosts adoption 154
10.2.2.5 Diffusion and flow-based models 155
10.2.2.5.1 Increasing demand for controlled generation of novel molecules and proteins accelerates segment growth 155
10.2.2.6 Generative adversarial networks (GAN) & variational autoencoders (VAE) 156
10.2.2.6.1 Growing demand for computational exploration of chemical space supports growth 156
10.2.2.7 Recurrent & Sequence Models (RNN, LSTM) 157
10.2.2.7.1 Continued need to model sequential chemical and biological information sustains demand 157
10.2.2.8 Other deep learning technologies 158
10.2.2.8.1 Emergence of specialized neural architectures expands applications across complex discovery workflows 158
10.2.3 SUPERVISED LEARNING 159
10.2.3.1 Growing availability of experimentally validated datasets supports segment 159
10.2.4 SELF-SUPERVISED & REPRESENTATION LEARNING 160
10.2.4.1 Shortage of labeled biological data and growing availability of unlabeled datasets drive adoption 160
10.2.5 REINFORCEMENT LEARNING 161
10.2.5.1 Need to optimize molecules and experimental decisions across multiple objectives drives adoption 161
10.2.6 UNSUPERVISED LEARNING 162
10.2.6.1 Increasing complexity of biological datasets to boost segment 162
10.2.7 OTHER MACHINE LEARNING TECHNOLOGIES 163
10.2.7.1 Need to extract value from partially labeled and heterogeneous datasets supports segment 163
10.3 GENERATIVE AI 164
10.3.1 ABILITY TO DESIGN NOVEL MOLECULES AND BIOLOGICAL STRUCTURES ACCELERATES ADOPTION 164
10.3.2 MOLECULAR GENERATIVE MODELS 165
10.3.2.1 Need to explore larger chemical spaces and simultaneously optimize multiple molecular properties – segment driver 165
10.3.3 PROTEIN & BIOLOGICS GENERATIVE MODELS 166
10.3.3.1 Growing demand for engineered proteins, antibodies, and other biologics expands applications 166
10.3.4 LARGE LANGUAGE MODELS (LLMS) 167
10.3.4.1 Rapid growth of scientific literature and unstructured research data increases demand 167
10.4 FOUNDATION MODELS 168
10.4.1 NEED FOR REUSABLE AI MODELS TO LEARN FROM LARGE-SCALE, MULTIMODAL BIOLOGICAL DATASETS DRIVES ADOPTION 168
10.4.2 CHEMISTRY FOUNDATION MODELS 169
10.4.2.1 Increasing need for reusable molecular representation and scalable chemical intelligence drives segment 169
10.4.3 PROTEIN LANGUAGE MODELS 170
10.4.3.1 Growing demand for protein engineering and functional prediction accelerates adoption 170
10.4.4 BIOLOGY AND MULTIOMICS FOUNDATION MODELS 171
10.4.4.1 Increasing integration of genomic, transcriptomic, proteomic, and cellular data – key driver 171
10.5 AGENTIC AI & AI CO-SCIENTISTS 172
10.5.1 GROWTH DRIVEN BY DEMAND FOR AUTONOMOUS RESEARCH WORKFLOWS AND IMPROVED SCIENTIST PRODUCTIVITY 172
10.5.2 AUTONOMOUS RESEARCH AGENTS & WORKFLOW ORCHESTRATION 173
10.5.2.1 Need to automate complex multi-step research processes drives adoption 173
10.5.3 MULTI-AGENT REASONING SYSTEMS 174
10.5.3.1 Increasing complexity of scientific problems creates demand 174
10.5.4 LAB-IN-THE-LOOP & CLOSED-LOOP EXPERIMENTATION 175
10.5.4.1 Integration of AI with automated laboratories enables continuous design–build–test–learn workflows 175
10.6 KNOWLEDGE GRAPHS AND SEMANTIC REASONING 176
10.6.1 NEED TO CONNECT FRAGMENTED SCIENTIFIC INFORMATION AND IDENTIFY HIDDEN RELATIONSHIPS DRIVES SEGMENT 176
10.7 NATURAL LANGUAGE PROCESSING (NLP) 177
10.7.1 EXPLOSION OF SCIENTIFIC LITERATURE, PATENTS, AND UNSTRUCTURED R&D INFORMATION DRIVES NLP ADOPTION 177
10.8 COMPUTER VISION & IMAGE ANALYSIS 178
10.8.1 INCREASING USE OF HIGH-CONTENT SCREENING, MICROSCOPY, AND PHENOTYPIC ASSAYS EXPANDS APPLICATIONS 178
10.9 PHYSICS-BASED & HYBRID AI METHODS 179
10.9.1 NEED FOR MECHANISTIC UNDERSTANDING AND IMPROVED ACCURACY IN MOLECULAR MODELING DRIVES SEGMENT 179
11 AI IN DRUG DISCOVERY MARKET, BY END USER 182
11.1 INTRODUCTION 183
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 183
11.2.1 GROWING PRESSURE TO ACCELERATE R&D PRODUCTIVITY AND REDUCE DRUG DISCOVERY COSTS DRIVES SEGMENT 183
11.2.2 LARGE PHARMACEUTICAL COMPANIES 185
11.2.2.1 High R&D expenditure and increasing need to improve pipeline productivity accelerate AI adoption 185
11.2.3 SMALL & MID-SIZED BIOTECHNOLOGY COMPANIES 186
11.2.3.1 Limited internal resources and need for differentiated pipelines increase reliance on AI-enabled discovery 186
11.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CDMOS 187
11.3.1 INCREASING OUTSOURCING OF DRUG DISCOVERY ACTIVITIES DRIVES GROWTH 187
11.4 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS 188
11.4.1 GROWING AVAILABILITY OF RESEARCH FUNDING AND ADVANCED AI CAPABILITIES EXPANDS GROWTH 188
12 AI IN DRUG DISCOVERY MARKET, BY USE CASE 190
12.1 INTRODUCTION 191
12.2 UNDERSTANDING DISEASE BIOLOGY 192
12.2.1 INCREASED FOCUS ON UNDERSTANDING DISEASES TO IMPROVE RESEARCH DATA QUALITY AND QUANTITY 192
12.2.2 EVIDENCE SYNTHESIS AND SCIENTIFIC LITERATURE INTELLIGENCE 194
12.2.2.1 Rapid data analysis – key demand driver 194
12.2.3 MULTIOMICS INTEGRATION & TARGET-DISEASE ASSOCIATION 195
12.2.3.1 Growing integration of genomic, transcriptomic, proteomic, metabolomic, and other biological datasets to drive market 195
12.2.4 EXPERIMENT DESIGN & REAGENT/MODEL SELECTION 196
12.2.4.1 Growing complexity of disease biology and experiment design boosts demand 196
12.3 PROTEIN STRUCTURE & INTERACTION PREDICTION 197
12.3.1 ADVANCES IN AI-POWERED PROTEIN INTERACTION PREDICTION ACCELERATE STRUCTURE-BASED DRUG DISCOVERY 197
12.4 DRUG REPURPOSING 198
12.4.1 INCREASING ADOPTION OF AI PLATFORMS FOR SYSTEMATIC DRUG REPURPOSING 198
12.5 DE NOVO DRUG DESIGN 199
12.5.1 SMALL MOLECULE DESIGN 200
12.5.1.1 Increasing use of virtual screening and simulation techniques to
drive growth 200
12.5.2 VACCINE DESIGN 201
12.5.2.1 Availability of well-validated AI tools to boost market growth 201
12.5.3 ANTIBODY & OTHER BIOLOGICS DESIGN 202
12.5.3.1 Advancements in protein modeling to propel segment growth 202
12.5.4 PROTEIN & ENZYME DESIGN 203
12.5.4.1 Protein designing to propel segment growth 203
12.6 DRUG OPTIMIZATION 204
12.6.1 SMALL MOLECULE OPTIMIZATION 205
12.6.1.1 Generative models for potential modifications in molecular structures to aid market growth 205
12.6.2 VACCINE OPTIMIZATION 206
12.6.2.1 Effective prediction of vaccine formulations and adjustment of delivery vectors to drive growth 206
12.6.3 ANTIBODY & OTHER BIOLOGICS OPTIMIZATION 207
12.6.3.1 Increasing adoption of machine learning to predict protein structures to augment segment growth 207
12.7 SAFETY & TOXICITY 209
12.7.1 FOCUS ON ADVANCED OFF-TARGET EFFECT PREDICTION, PK/PD SIMULATION, AND QSP MODELING TO DRIVE MARKET 209
13 AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT 211
13.1 INTRODUCTION 212
13.2 ON-PREMISE SOLUTIONS 212
13.2.1 GROWING DEMAND FOR DATA SOVEREIGNTY, IP PROTECTION, AND CONTROL OVER PROPRIETARY R&D DATA SUPPORTS GROWTH DEPLOYMENT 212
13.3 CLOUD-BASED SOLUTIONS 213
13.3.1 NEED FOR SCALABLE COMPUTING, RAPID AI DEPLOYMENT, AND COST-EFFICIENT ACCESS TO ADVANCED INFRASTRUCTURE - KEY DRIVERS 213
13.3.2 PUBLIC CLOUD 214
13.3.2.1 Elastic computing capacity and access to advanced AI infrastructure drive adoption 214
13.3.3 PRIVATE CLOUD/VPC/SOVEREIGN DEPLOYMENT 215
13.3.3.1 Increasing data-security, IP-protection, and data-residency requirements strengthen demand 215
13.4 HYBRID SOLUTIONS 216
13.4.1 NEED TO BALANCE COMPUTATIONAL SCALABILITY WITH CONTROL OVER SENSITIVE R&D DATA ACCELERATES ADOPTION 216
14 AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 218
14.1 INTRODUCTION 219
14.2 ONCOLOGY 219
14.2.1 HIGH PREVALENCE OF ONCOLOGY AND SHORTAGE OF EFFECTIVE ONCOLOGY DRUGS TO DRIVE MARKET GROWTH 219
14.3 INFECTIOUS DISEASES 220
14.3.1 RISING ANTIMICROBIAL RESISTANCE AND NEED FOR NOVEL ANTI-INFECTIVE THERAPIES TO DRIVE GROWTH 220
14.4 NEUROLOGY 221
14.4.1 HIGH DISEASE COMPLEXITY AND LIMITED TREATMENT OPTIONS DRIVE DEMAND FOR AI-ENABLED DISCOVERY 221
14.5 CARDIOVASCULAR DISEASES 223
14.5.1 GROWING CARDIOVASCULAR DISEASE BURDEN AND NEED FOR NOVEL THERAPEUTIC TARGETS BOOST GROWTH 223
14.6 METABOLIC DISEASES 224
14.6.1 RISING PREVALENCE OF OBESITY AND METABOLIC DISORDERS ACCELERATES DEMAND FOR INNOVATIVE THERAPIES 224
14.7 IMMUNOLOGY 225
14.7.1 COMPLEX IMMUNE MECHANISMS AND GROWING DEMAND FOR TARGETED THERAPIES DRIVE AI ADOPTION 225
14.8 RARE & GENETIC DISORDERS 226
14.8.1 LIMITED TREATMENT OPTIONS AND FRAGMENTED DISEASE DATA DRIVE
AI-ENABLED DRUG DISCOVERY 226
14.9 MENTAL HEALTH DISORDERS 227
14.9.1 HIGH UNMET NEED AND LIMITED UNDERSTANDING OF DISEASE MECHANISMS DRIVE SEGMENT GROWTH 227
14.10 OTHER THERAPEUTIC AREAS 228
14.10.1 EXPANDING APPLICATION OF AI ACROSS UNDEREXPLORED DISEASE AREAS DRIVES MARKET GROWTH 228
15 AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE 230
15.1 INTRODUCTION 231
15.2 END-TO-END SOLUTION PROVIDERS 231
15.2.1 INCREASING ADOPTION OF INTEGRATED AI PLATFORMS ACROSS DRUG DISCOVERY WORKFLOW DRIVES GROWTH 231
15.3 NICHE/POINT SOLUTION PROVIDERS 232
15.3.1 GROWING DEMAND FOR SPECIALIZED AI CAPABILITIES TARGETING COMPLEX DISCOVERY CHALLENGES TO DRIVE GROWTH 232
15.4 AI TECHNOLOGY PROVIDERS 233
15.4.1 RAPID ADVANCES IN GENERATIVE AI, FOUNDATION MODELS, AND AGENTIC AI ACCELERATE DEMAND 233
15.5 COMPUTE & INFRASTRUCTURE PROVIDERS 234
15.5.1 GROWING COMPUTATIONAL REQUIREMENTS OF ADVANCED AI MODELS DRIVE DEMAND 234
15.6 BUSINESS PROCESS SERVICE PROVIDERS 235
15.6.1 INCREASING OUTSOURCING OF SPECIALIZED AI-ENABLED DISCOVERY ACTIVITIES DRIVES GROWTH 235
16 AI IN DRUG DISCOVERY MARKET, BY REGION 237
16.1 INTRODUCTION 238
16.2 NORTH AMERICA 238
16.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 239
16.2.2 US 248
16.2.2.1 Strong pharma–AI ecosystem and high R&D investment
drives demand 248
16.2.3 CANADA 257
16.2.3.1 Strong AI research base and growing biopharma innovation
– key drivers 257
16.3 EUROPE 265
16.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 265
16.3.2 GERMANY 274
16.3.2.1 Availability of advanced computing and research infrastructure
– key market driver 274
16.3.3 UK 282
16.3.3.1 Increasing investment in AI-based molecular design drives demand 282
16.3.4 SWITZERLAND 290
16.3.4.1 Strong pharmaceutical and biotechnology ecosystem to boost market 290
16.3.5 FRANCE 298
16.3.5.1 Large-scale AI investment by pharmaceutical companies – key driver 298
16.3.6 ITALY 306
16.3.6.1 Market driven by country’s strong pharmaceutical and life
sciences ecosystem 306
16.3.7 SPAIN 314
16.3.7.1 Expansion of AI-enabled biotechnology research drives demand 314
16.3.8 REST OF EUROPE 322
16.3.8.1 Growing pharmaceutical R&D and public-sector AI adoption to
drive market 322
16.4 ASIA PACIFIC 330
16.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 331
16.4.2 JAPAN 340
16.4.2.1 Increasing pharmaceutical investment in AI and robotics
drives demand 340
16.4.3 CHINA 348
16.4.3.1 Growth of AI-native biotech companies boosts demand 348
16.4.4 INDIA 357
16.4.4.1 Large pharmaceutical and biotechnology ecosystem to propel market 357
16.4.5 SOUTH KOREA 365
16.4.5.1 Government support for AI-based drug discovery to boost market 365
16.4.6 AUSTRALIA 374
16.4.6.1 Market driven by strong government support for AI and
medical research 374
16.4.7 REST OF ASIA PACIFIC 382
16.4.7.1 Growth of regional pharmaceutical and biotechnology capabilities to boost market 382
16.5 LATIN AMERICA 391
16.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 392
16.5.2 BRAZIL 400
16.5.2.1 Expanding pharmaceutical R&D and emerging AI-biotech ecosystem act as major drivers 400
16.5.3 MEXICO 408
16.5.3.1 Multinational pharmaceutical activity and government-backed research to drive market 408
16.5.4 REST OF LATIN AMERICA 416
16.5.4.1 Growing research base for AI to drive market 416
16.6 MIDDLE EAST & AFRICA 425
16.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 425
16.6.2 GCC COUNTRIES 434
16.6.2.1 National AI strategies and growing technology partnerships act as major drivers 434
16.6.3 SAUDI ARABIA 442
16.6.3.1 Government investment in biotechnology and life sciences propels market 442
16.6.4 UAE 450
16.6.4.1 Government-led AI and biotechnology investment boosts market 450
16.6.5 REST OF GCC 459
16.6.5.1 International AI-drug discovery partnerships drive demand 459
16.6.6 SOUTH AFRICA 467
16.6.6.1 Strong domestic drug-discovery research base drives market 467
16.6.7 REST OF MIDDLE EAST & AFRICA 475
16.6.7.1 Expansion of local pharmaceutical and biomanufacturing capabilities drives demand 475
17 COMPETITIVE LANDSCAPE 484
17.1 OVERVIEW 484
17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 484
17.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN DRUG DISCOVERY MARKET 485
17.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 488
17.4 MARKET SHARE ANALYSIS, 2025 489
17.5 BRAND COMPARISON 491
17.6 VALUATION & FINANCIAL METRICS 492
17.6.1 FINANCIAL METRICS 492
17.6.2 COMPANY VALUATION 492
17.7 COMPANY EVALUATION MATRIX 493
17.7.1 STARS 493
17.7.2 EMERGING LEADERS 493
17.7.3 PERVASIVE PLAYERS 493
17.7.4 PARTICIPANTS 494
17.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 495
17.7.5.1 Company footprint 495
17.7.5.2 Region footprint 496
17.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 502
17.8.1 PROGRESSIVE COMPANIES 502
17.8.2 RESPONSIVE COMPANIES 502
17.8.3 DYNAMIC COMPANIES 502
17.8.4 STARTING BLOCKS 502
17.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 504
17.8.5.1 Detailed list of key startups/SMEs 504
17.8.5.2 Competitive benchmarking of startups/SMEs 505
17.9 COMPETITIVE SCENARIO 505
17.9.1 PRODUCT/SERVICE LAUNCHES 505
17.9.2 DEALS 506
17.9.3 EXPANSIONS 507
17.9.4 OTHER DEVELOPMENTS 507
18 COMPANY PROFILES 508
18.1 KEY PLAYERS 508
18.1.1 NVIDIA CORPORATION 508
18.1.1.1 Business overview 508
18.1.1.2 Products/Services offered 510
18.1.1.3 Recent developments 511
18.1.1.3.1 Product/Service launches & approvals 511
18.1.1.3.2 Deals 512
18.1.1.3.3 Other developments 515
18.1.1.4 MnM view 515
18.1.1.4.1 Right to win 515
18.1.1.4.2 Strategic choices 516
18.1.1.4.3 Weaknesses & competitive threats 516
18.1.2 ALPHABET INC. 517
18.1.2.1 Business overview 517
18.1.2.2 Products/Services offered 518
18.1.2.3 Recent developments 519
18.1.2.3.1 Product launches & approvals 519
18.1.2.3.2 Deals 520
18.1.2.3.3 Other developments 521
18.1.2.4 MnM view 521
18.1.2.4.1 Right to win 521
18.1.2.4.2 Strategic choices 521
18.1.2.4.3 Weaknesses & competitive threats 521
18.1.3 RECURSION 522
18.1.3.1 Business overview 522
18.1.3.2 Products/Services offered 523
18.1.3.3 Recent developments 524
18.1.3.3.1 Product/Service launches 524
18.1.3.3.2 Deals 524
18.1.3.3.3 Expansions 526
18.1.3.4 MnM view 527
18.1.3.4.1 Right to win 527
18.1.3.4.2 Strategic choices 527
18.1.3.4.3 Weaknesses & competitive threats 527
18.1.4 INSILICO MEDICINE 528
18.1.4.1 Business overview 528
18.1.4.2 Products/Services offered 529
18.1.4.3 Recent developments 530
18.1.4.3.1 Product/Service launches 530
18.1.4.3.2 Deals 531
18.1.4.3.3 Other developments 534
18.1.4.3.4 expansions 534
18.1.4.4 MnM view 534
18.1.4.4.1 Right to win 534
18.1.4.4.2 Strategic choices 535
18.1.4.4.3 Weaknesses & competitive threats 535
18.1.5 SCHRÖDINGER, INC. 536
18.1.5.1 Business overview 536
18.1.5.2 Products/Services offered 537
18.1.5.3 Recent developments 538
18.1.5.3.1 Deals 538
18.1.5.3.2 Other developments 539
18.1.5.4 MnM view 540
18.1.5.4.1 Right to win 540
18.1.5.4.2 Strategic choices 540
18.1.5.4.3 Weaknesses & competitive threats 540
18.1.6 BENEVOLENTAI 541
18.1.6.1 Business overview 541
18.1.6.2 Products/Services offered 542
18.1.6.3 Recent developments 542
18.1.6.3.1 Deals 542
18.1.7 MICROSOFT CORPORATION 544
18.1.7.1 Business overview 544
18.1.7.2 Products /Services offered 545
18.1.7.3 Recent developments 546
18.1.7.3.1 Product/Service launches & approvals 546
18.1.7.3.2 Deals 546
18.1.8 NUMERION LABS 548
18.1.8.1 Business overview 548
18.1.8.2 Products/Services offered 549
18.1.9 ILLUMINA, INC. 550
18.1.9.1 Business overview 550
18.1.9.2 Products/Services offered 551
18.1.9.3 Recent developments 553
18.1.9.3.1 Product/Service launches 553
18.1.9.3.2 Deals 554
18.1.10 XTALPI INC. 556
18.1.10.1 Business overview 556
18.1.10.2 Products/Services offered 557
18.1.10.3 Recent developments 558
18.1.10.3.1 Deals 558
18.1.11 IKTOS 560
18.1.11.1 Business overview 560
18.1.11.2 Products/Services offered 561
18.1.11.3 Recent developments 562
18.1.11.3.1 Deals 562
18.1.11.3.2 Other developments 563
18.1.12 TEMPUS AI, INC. 564
18.1.12.1 Business overview 564
18.1.12.2 Products/Services offered 565
18.1.12.3 Recent developments 566
18.1.12.3.1 Product/Service launches 566
18.1.12.3.2 Deals 567
18.1.13 DEEP GENOMICS, INC. 570
18.1.13.1 Business overview 570
18.1.13.2 Products/Services offered 570
18.1.13.3 Recent developments 571
18.1.13.3.1 Product/Service launches & approvals 571
18.1.14 VERGE LABS 572
18.1.14.1 Business overview 572
18.1.14.2 Products /Services offered 573
18.1.14.3 Recent developments 573
18.1.14.3.1 Deals 573
18.1.15 BENCHSCI 575
18.1.15.1 Business overview 575
18.1.15.2 Products/Services offered 575
18.1.15.3 Recent developments 576
18.1.15.3.1 Product/Service launches & approvals 576
18.1.15.3.2 Deals 576
18.1.15.3.3 Other developments 577
18.1.16 INSITRO 578
18.1.16.1 Business overview 578
18.1.16.2 Products/Services offered 578
18.1.16.3 Recent developments 579
18.1.16.3.1 Deals 579
18.1.16.3.2 Other developments 579
18.1.17 VALO HEALTH 580
18.1.17.1 Business overview 580
18.1.17.2 Products/Services offered 580
18.1.17.3 Recent developments 581
18.1.17.3.1 Deals 581
18.1.17.3.2 Other developments 582
18.1.18 BPGBIO, INC. 583
18.1.18.1 Business overview 583
18.1.18.2 Products/Services offered 583
18.1.18.3 Recent developments 584
18.1.18.3.1 Deals 584
18.1.19 GENERATE:BIOMEDICINES 585
18.1.19.1 Business overview 585
18.1.19.2 Products/Services offered 585
18.1.19.3 Recent developments 586
18.1.19.3.1 Product/Service launches 586
18.1.19.3.2 Deals 587
18.1.19.3.3 Expansions 588
18.1.20 CERTARA, INC. 589
18.1.20.1 Business overview 589
18.1.20.2 Products/Services offered 590
18.1.20.3 Recent developments 591
18.1.20.3.1 Product/Service launches & approvals 591
18.1.20.3.2 Deals 592
18.2 OTHER EMERGING PLAYERS 594
18.2.1 XAIRA THERAPEUTICS 594
18.2.2 IAMBIC THERAPEUTICS, INC. 595
18.2.3 GENESIS MOLECULAR AI 596
18.2.4 CRADLE BIO 597
18.2.5 ISOMORPHIC LABS 598
19 RESEARCH METHODOLOGY 599
19.1 RESEARCH APPROACH 599
19.1.1 SECONDARY RESEARCH 600
19.1.1.1 Key data from secondary sources 601
19.1.2 PRIMARY RESEARCH 601
19.1.2.1 Primary sources 602
19.1.2.2 Key data from primary sources 603
19.1.2.3 Breakdown of primaries 603
19.1.2.4 Insights from primary experts 604
19.2 RESEARCH METHODOLOGY DESIGN 604
19.3 MARKET SIZE ESTIMATION 606
19.4 MARKET BREAKDOWN DATA TRIANGULATION 612
19.5 MARKET SHARE ESTIMATION 612
19.6 STUDY ASSUMPTIONS 613
19.7 RESEARCH LIMITATIONS 613
19.7.1 METHODOLOGY-RELATED LIMITATIONS 613
19.8 RISK ASSESSMENT 614
20 APPENDIX 615
20.1 DISCUSSION GUIDE 615
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 626
20.3 CUSTOMIZATION OPTIONS 628
20.4 RELATED REPORTS 628
20.5 AUTHOR DETAILS 629
圖表清單 List of Tables & Figures
TABLE 1 USD EXCHANGE RATES 54
TABLE 2 AI IN DRUG DISCOVERY: COLLABORATIONS AND PARTNERSHIPS, 2024–2026 69
TABLE 3 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2025 AND 2026 71
TABLE 4 AI IN DRUG DISCOVERY MARKET: ROLE IN ECOSYSTEM 92
TABLE 5 INDICATIVE PRICE FOR AI IN DRUG DISCOVERY PLATFORMS,
BY KEY PLAYERS, 2025 93
TABLE 6 INDICATIVE PRICE FOR AI IN DRUG DISCOVERY MARKET, BY REGION (2025) 95
TABLE 7 KEY CONFERENCES & EVENTS IN AI IN DRUG DISCOVERY MARKET,
JULY 2026-JUNE 2027 96
TABLE 8 CASE 1: TERRAY THERAPEUTICS’ USE OF NVIDIA TO ACCELERATE GENERATIVE
AI-ENABLED SMALL-MOLECULE DRUG DISCOVERY 99
TABLE 9 CASE 2: ASTELLAS PHARMA’S USE OF NVIDIA AI TO ACCELERATE BIOMOLECULAR DISCOVERY AND COMPOUND SCREENING 100
TABLE 10 CASE 3: AMGEN–NVIDIA COLLABORATION ACCELERATES BIOLOGICS DISCOVERY THROUGH GENERATIVE AI 100
TABLE 11 US ADJUSTED RECIPROCAL TARIFF RATES 101
TABLE 12 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN DRUG DISCOVERY 109
TABLE 13 AI IN DRUG DISCOVERY MARKET: KEY PATENTS/PATENT APPLICATIONS 111
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 115
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 116
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 117
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 118
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 119
TABLE 19 REGULATORY SCENARIO OF NORTH AMERICA 121
TABLE 20 REGULATORY SCENARIO OF EUROPE 121
TABLE 21 REGULATORY SCENARIO OF ASIA PACIFIC 123
TABLE 22 REGULATORY SCENARIO OF LATIN AMERICA 125
TABLE 23 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA 126
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF
TOP THREE END USERS (%) 131
TABLE 25 KEY BUYING CRITERIA FOR TOP THREE END USERS 132
TABLE 26 AI IN DRUG DISCOVERY MARKET: UNMET NEEDS 133
TABLE 27 DRUG DISCOVERY MARKET: END USER EXPECTATIONS 134
TABLE 28 AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION) 137
TABLE 29 AI IN DRUG DISCOVERY MARKET FOR TARGET IDENTIFICATION & SELECTION,
BY REGION, 2024–2031 (USD MILLION) 138
TABLE 30 AI IN DRUG DISCOVERY MARKET FOR TARGET VALIDATION, BY REGION,
2024–2031 (USD MILLION) 140
TABLE 31 AI IN DRUG DISCOVERY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION,
BY REGION, 2024–2031 (USD MILLION) 141
TABLE 32 AI IN DRUG DISCOVERY MARKET FOR HIT TO LEAD IDENTIFICATION/LEAD GENERATION, BY REGION, 2024–2031 (USD MILLION) 142
TABLE 33 AI IN DRUG DISCOVERY MARKET FOR LEAD OPTIMIZATION, BY REGION,
2024–2031 (USD MILLION) 143
TABLE 34 AI IN DRUG DISCOVERY MARKET FOR CANDIDATE SELECTION & VALIDATION,
BY REGION, 2024–2031 (USD MILLION) 145
TABLE 35 AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION) 147
TABLE 36 MACHINE LEARNING: AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 149
TABLE 37 MACHINE LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 149
TABLE 38 DEEP LEARNING: AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 151
TABLE 39 DEEP LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 151
TABLE 40 TRANSFORMER-BASED ARCHITECTURE: AI IN DRUG DISCOVERY MARKET,
BY REGION, 2024–2031 (USD MILLION) 152
TABLE 41 GRAPH NEURAL NETWORKS: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 153
TABLE 42 CONVOLUTIONAL NEURAL NETWORKS: AI IN DRUG DISCOVERY MARKET,
BY REGION, 2024–2031 (USD MILLION) 154
TABLE 43 DIFFUSION AND FLOW-BASED MODELS: AI IN DRUG DISCOVERY MARKET,
BY REGION, 2024–2031 (USD MILLION) 155
TABLE 44 GAN & VAE: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 156
TABLE 45 RECURRENT & SEQUENCE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 157
TABLE 46 OTHER DEEP LEARNING TECHNOLOGIES: AI IN DRUG DISCOVERY MARKET,
BY REGION, 2024–2031 (USD MILLION) 158
TABLE 47 SUPERVISED LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 159
TABLE 48 SELF-SUPERVISED & REPRESENTATION LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 160
TABLE 49 REINFORCEMENT LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 161
TABLE 50 UNSUPERVISED LEARNING: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 162
TABLE 51 OTHER MACHINE LEARNING TECHNOLOGIES: AI IN DRUG DISCOVERY MARKET,
BY REGION, 2024–2031 (USD MILLION) 163
TABLE 52 GENERATIVE AI: AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 165
TABLE 53 GENERATIVE AI: AI IN DRUG DISCOVERY, BY REGION, 2024–2031 (USD MILLION) 165
TABLE 54 MOLECULAR GENERATIVE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 166
TABLE 55 PROTEIN & BIOLOGICS GENERATIVE MODELS: AI IN DRUG DISCOVERY MARKET,
BY REGION, 2024–2031 (USD MILLION) 167
TABLE 56 LARGE LANGUAGE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 168
TABLE 57 FOUNDATION MODELS: AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 169
TABLE 58 FOUNDATION MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 169
TABLE 59 CHEMISTRY FOUNDATION MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 170
TABLE 60 PROTEIN LANGUAGE MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 171
TABLE 61 BIOLOGY AND MULTIOMICS FOUNDATION MODELS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 172
TABLE 62 AGENTIC AI & CO-SCIENTISTS: AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 173
TABLE 63 AGENTIC AI & CO-SCIENTISTS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 173
TABLE 64 AUTONOMOUS RESEARCH AGENTS & WORKFLOW ORCHESTRATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 174
TABLE 65 MULTI-AGENT REASONING SYSTEMS: AI IN DRUG DISCOVERY MARKET,
BY REGION, 2024–2031 (USD MILLION) 175
TABLE 66 LAB-IN-THE-LOOP & CLOSED-LOOP EXPERIMENTATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 176
TABLE 67 KNOWLEDGE GRAPHS AND SEMANTIC REASONING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 177
TABLE 68 NATURAL LANGUAGE PROCESSING: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 178
TABLE 69 COMPUTER VISION & IMAGE ANALYSIS: AI IN DRUG DISCOVERY MARKET,
BY REGION, 2024–2031 (USD MILLION) 179
TABLE 70 PHYSICS-BASED & HYBRID AI MODELS: AI IN DRUG DISCOVERY MARKET,
BY REGION, 2024–2031 (USD MILLION) 181
TABLE 71 AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION) 183
TABLE 72 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 184
TABLE 73 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 184
TABLE 74 LARGE PHARMACEUTICAL COMPANIES: AI IN DRUG DISCOVERY MARKET,
BY REGION, 2024–2031 (USD MILLION) 185
TABLE 75 SMALL & MID-SIZED BIOTECHNOLOGY COMPANIES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 186
TABLE 76 CROS & CDMOS: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 188
TABLE 77 RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 189
TABLE 78 AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION) 191
TABLE 79 UNDERSTANDING DISEASE BIOLOGY: AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 193
TABLE 80 UNDERSTANDING DISEASE BIOLOGY: AI IN DRUG DISCOVERY MARKET,
BY REGION, 2024–2031 (USD MILLION) 194
TABLE 81 EVIDENCE SYNTHESIS AND SCIENTIFIC LITERATURE INTELLIGENCE: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 195
TABLE 82 MULTIOMICS INTEGRATION & TARGET DISEASE ASSOCIATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 196
TABLE 83 EXPERIMENT DESIGN & REAGENT/MODEL SELECTION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 197
TABLE 84 PROTEIN STRUCTURE & INTERACTION PREDICTION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 198
TABLE 85 DRUG REPURPOSING: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 199
TABLE 86 DE NOVO DRUG DESIGN: AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 200
TABLE 87 DE NOVO DRUG DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 200
TABLE 88 SMALL MOLECULE DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 201
TABLE 89 VACCINE DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 202
TABLE 90 ANTIBODY & OTHER BIOLOGICS DESIGN: AI IN DRUG DISCOVERY MARKET,
BY REGION, 2024–2031 (USD MILLION) 203
TABLE 91 PROTEIN & ENZYME DESIGN: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 204
TABLE 92 DRUG OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 205
TABLE 93 DRUG OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 205
TABLE 94 SMALL MOLECULE OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 206
TABLE 95 VACCINE OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 207
TABLE 96 ANTIBODY & OTHER BIOLOGICS OPTIMIZATION: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 208
TABLE 97 SAFETY & TOXICITY: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 210
TABLE 98 AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION) 212
TABLE 99 ON-PREMISE SOLUTIONS: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 213
TABLE 100 CLOUD-BASED SOLUTIONS: AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 214
TABLE 101 CLOUD-BASED SOLUTIONS: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 214
TABLE 102 PUBLIC DEPLOYMENT: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 215
TABLE 103 PRIVATE CLOUD/VPC/SOVEREIGN DEPLOYMENT: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 216
TABLE 104 HYBRID SOLUTIONS: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 217
TABLE 105 AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 219
TABLE 106 ONCOLOGY: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 220
TABLE 107 INFECTIOUS DISEASES: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 221
TABLE 108 NEUROLOGY: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 222
TABLE 109 CARDIOVASCULAR DISEASES: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 224
TABLE 110 METABOLIC DISEASES: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 225
TABLE 111 IMMUNOLOGY: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 226
TABLE 112 RARE & GENETIC DISORDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 227
TABLE 113 MENTAL DISORDERS: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 228
TABLE 114 OTHER THERAPEUTIC AREAS: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 229
TABLE 115 AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION) 231
TABLE 116 END-TO-END SOLUTION PROVIDERS: AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 232
TABLE 117 NICHE/POINT SOLUTION PROVIDERS: AI IN DRUG DISCOVERY MARKET,
BY REGION, 2024–2031 (USD MILLION) 233
TABLE 118 AI TECHNOLOGY PROVIDERS: AI IN DRUG DISCOVERY MARKET, BY REGION,
2024–2031 (USD MILLION) 234
TABLE 119 COMPUTE & INFRASTRUCTURE PROVIDERS: AI IN DRUG DISCOVERY MARKET,
BY REGION, 2024–2031 (USD MILLION) 235
TABLE 120 BUSINESS PROCESS SERVICE PROVIDERS: AI IN DRUG DISCOVERY MARKET,
BY REGION, 2024–2031 (USD MILLION) 236
TABLE 121 AI IN DRUG DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION) 238
TABLE 122 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 240
TABLE 123 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 240
TABLE 124 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 241
TABLE 125 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 241
TABLE 126 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 242
TABLE 127 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION,
BY TYPE, 2024–2031 (USD MILLION) 242
TABLE 128 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 243
TABLE 129 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 243
TABLE 130 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL,
2024–2031 (USD MILLION) 244
TABLE 131 NORTH AMERICA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 132 NORTH AMERICA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 245
TABLE 133 NORTH AMERICA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 245
TABLE 134 NORTH AMERICA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 135 NORTH AMERICA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 136 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 247
TABLE 137 NORTH AMERICA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 247
TABLE 138 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 247
TABLE 139 NORTH AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 140 US: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION) 249
TABLE 141 US: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION) 250
TABLE 142 US: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 250
TABLE 143 US: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 251
TABLE 144 US: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE,
2024–2031 (USD MILLION) 251
TABLE 145 US: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 252
TABLE 146 US: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 252
TABLE 147 US: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION) 253
TABLE 148 US: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 253
TABLE 149 US: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 254
TABLE 150 US: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 254
TABLE 151 US: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 255
TABLE 152 US: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 255
TABLE 153 US: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 255
TABLE 154 US: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 256
TABLE 155 US: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION) 256
TABLE 156 US: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 256
TABLE 157 CANADA: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 257
TABLE 158 CANADA: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 258
TABLE 159 CANADA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 258
TABLE 160 CANADA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 161 CANADA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 162 CANADA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 260
TABLE 163 CANADA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 260
TABLE 164 CANADA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL,
2024–2031 (USD MILLION) 261
TABLE 165 CANADA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 261
TABLE 166 CANADA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 262
TABLE 167 CANADA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 262
TABLE 168 CANADA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 263
TABLE 169 CANADA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 263
TABLE 170 CANADA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 263
TABLE 171 CANADA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 264
TABLE 172 CANADA: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 264
TABLE 173 CANADA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 264
TABLE 174 EUROPE: AI IN DRUG DISCOVERY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 266
TABLE 175 EUROPE: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 267
TABLE 176 EUROPE: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 267
TABLE 177 EUROPE: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 268
TABLE 178 EUROPE: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 268
TABLE 179 EUROPE: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION) 269
TABLE 180 EUROPE: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 269
TABLE 181 EUROPE: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 270
TABLE 182 EUROPE: AI IN DRUG DISCOVERY MARKET, BY AI TOOL,
2024–2031 (USD MILLION) 270
TABLE 183 EUROPE: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 271
TABLE 184 EUROPE: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 271
TABLE 185 EUROPE: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 272
TABLE 186 EUROPE: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 272
TABLE 187 EUROPE: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 272
TABLE 188 EUROPE: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 273
TABLE 189 EUROPE: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 273
TABLE 190 EUROPE: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 273
TABLE 191 EUROPE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 274
TABLE 192 GERMANY: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 275
TABLE 193 GERMANY: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 275
TABLE 194 GERMANY: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 276
TABLE 195 GERMANY: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN,
BY TYPE, 2024–2031 (USD MILLION) 276
TABLE 196 GERMANY: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION) 277
TABLE 197 GERMANY: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 277
TABLE 198 GERMANY: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 278
TABLE 199 GERMANY: AI IN DRUG DISCOVERY MARKET, BY AI TOOL,
2024–2031 (USD MILLION) 278
TABLE 200 GERMANY: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 279
TABLE 201 GERMANY: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 279
TABLE 202 GERMANY: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 280
TABLE 203 GERMANY: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 280
TABLE 204 GERMANY: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 280
TABLE 205 GERMANY: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 281
TABLE 206 GERMANY: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 281
TABLE 207 GERMANY: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 281
TABLE 208 GERMANY: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 282
TABLE 209 UK: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION) 283
TABLE 210 UK: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION) 283
TABLE 211 UK: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 284
TABLE 212 UK: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 284
TABLE 213 UK: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE,
2024–2031 (USD MILLION) 285
TABLE 214 UK: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 285
TABLE 215 UK: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 286
TABLE 216 UK: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION) 286
TABLE 217 UK: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 287
TABLE 218 UK: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 287
TABLE 219 UK: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 288
TABLE 220 UK: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 288
TABLE 221 UK: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 288
TABLE 222 UK: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 289
TABLE 223 UK: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 289
TABLE 224 UK: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION) 289
TABLE 225 UK: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 290
TABLE 226 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 291
TABLE 227 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 291
TABLE 228 SWITZERLAND: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 292
TABLE 229 SWITZERLAND: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN,
BY TYPE, 2024–2031 (USD MILLION) 292
TABLE 230 SWITZERLAND: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION,
BY TYPE, 2024–2031 (USD MILLION) 293
TABLE 231 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 293
TABLE 232 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 294
TABLE 233 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY AI TOOL,
2024–2031 (USD MILLION) 294
TABLE 234 SWITZERLAND: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 295
TABLE 235 SWITZERLAND: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 295
TABLE 236 SWITZERLAND: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 296
TABLE 237 SWITZERLAND: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 296
TABLE 238 SWITZERLAND: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 296
TABLE 239 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 297
TABLE 240 SWITZERLAND: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 297
TABLE 241 SWITZERLAND: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 297
TABLE 242 SWITZERLAND: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 298
TABLE 243 FRANCE: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 299
TABLE 244 FRANCE: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 299
TABLE 245 FRANCE: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 300
TABLE 246 FRANCE: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 300
TABLE 247 FRANCE: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION) 301
TABLE 248 FRANCE: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 301
TABLE 249 FRANCE: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 302
TABLE 250 FRANCE: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION) 302
TABLE 251 FRANCE: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 303
TABLE 252 FRANCE: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 303
TABLE 253 FRANCE: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 304
TABLE 254 FRANCE: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 304
TABLE 255 FRANCE: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 304
TABLE 256 FRANCE: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 305
TABLE 257 FRANCE: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 305
TABLE 258 FRANCE: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 305
TABLE 259 FRANCE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 306
TABLE 260 ITALY: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION) 307
TABLE 261 ITALY: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION) 307
TABLE 262 ITALY: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 308
TABLE 263 ITALY: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 308
TABLE 264 ITALY: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE,
2024–2031 (USD MILLION) 309
TABLE 265 ITALY: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 309
TABLE 266 ITALY: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 310
TABLE 267 ITALY: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION) 310
TABLE 268 ITALY: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 311
TABLE 269 ITALY: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 311
TABLE 270 ITALY: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 312
TABLE 271 ITALY: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 312
TABLE 272 ITALY: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 312
TABLE 273 ITALY: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 313
TABLE 274 ITALY: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 313
TABLE 275 ITALY: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION) 313
TABLE 276 ITALY: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 314
TABLE 277 SPAIN: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION) 315
TABLE 278 SPAIN: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 315
TABLE 279 SPAIN: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 316
TABLE 280 SPAIN: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 316
TABLE 281 SPAIN: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION) 317
TABLE 282 SPAIN: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 317
TABLE 283 SPAIN: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 318
TABLE 284 SPAIN: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION) 318
TABLE 285 SPAIN: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 319
TABLE 286 SPAIN: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 319
TABLE 287 SPAIN: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 320
TABLE 288 SPAIN: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 320
TABLE 289 SPAIN: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 320
TABLE 290 SPAIN: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 321
TABLE 291 SPAIN: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 321
TABLE 292 SPAIN: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 321
TABLE 293 SPAIN: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 322
TABLE 294 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 323
TABLE 295 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 323
TABLE 296 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 324
TABLE 297 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 324
TABLE 298 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION,
BY TYPE, 2024–2031 (USD MILLION) 325
TABLE 299 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 325
TABLE 300 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 326
TABLE 301 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY AI TOOL,
2024–2031 (USD MILLION) 326
TABLE 302 REST OF EUROPE: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 327
TABLE 303 REST OF EUROPE: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 327
TABLE 304 REST OF EUROPE: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 328
TABLE 305 REST OF EUROPE: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 328
TABLE 306 REST OF EUROPE: AGENTIC AI & CO-SCIENTISTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 328
TABLE 307 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 329
TABLE 308 REST OF EUROPE: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 329
TABLE 309 REST OF EUROPE: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 329
TABLE 310 REST OF EUROPE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 330
TABLE 311 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 332
TABLE 312 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 333
TABLE 313 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 333
TABLE 314 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 334
TABLE 315 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN,
BY TYPE, 2024–2031 (USD MILLION) 334
TABLE 316 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION) 335
TABLE 317 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 335
TABLE 318 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 336
TABLE 319 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY AI TOOL,
2024–2031 (USD MILLION) 336
TABLE 320 ASIA PACIFIC: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 337
TABLE 321 ASIA PACIFIC: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 337
TABLE 322 ASIA PACIFIC: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 338
TABLE 323 ASIA PACIFIC: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 338
TABLE 324 ASIA PACIFIC: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 338
TABLE 325 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 339
TABLE 326 ASIA PACIFIC: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 339
TABLE 327 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 339
TABLE 328 ASIA PACIFIC: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 340
TABLE 329 JAPAN: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 341
TABLE 330 JAPAN: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 341
TABLE 331 JAPAN: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 342
TABLE 332 JAPAN: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 342
TABLE 333 JAPAN: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION) 343
TABLE 334 JAPAN: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 343
TABLE 335 JAPAN: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 344
TABLE 336 JAPAN: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION) 344
TABLE 337 JAPAN: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 345
TABLE 338 JAPAN: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 345
TABLE 339 JAPAN: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 346
TABLE 340 JAPAN: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 346
TABLE 341 JAPAN: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 347
TABLE 342 JAPAN: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 347
TABLE 343 JAPAN: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 347
TABLE 344 JAPAN: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 348
TABLE 345 JAPAN: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 348
TABLE 346 CHINA: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 349
TABLE 347 CHINA: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 350
TABLE 348 CHINA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 350
TABLE 349 CHINA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 351
TABLE 350 CHINA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION) 351
TABLE 351 CHINA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 352
TABLE 352 CHINA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 352
TABLE 353 CHINA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION) 353
TABLE 354 CHINA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 353
TABLE 355 CHINA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 354
TABLE 356 CHINA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 354
TABLE 357 CHINA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 355
TABLE 358 CHINA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 355
TABLE 359 CHINA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 355
TABLE 360 CHINA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 356
TABLE 361 CHINA: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 356
TABLE 362 CHINA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 356
TABLE 363 INDIA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION) 358
TABLE 364 INDIA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION) 358
TABLE 365 INDIA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 359
TABLE 366 INDIA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 359
TABLE 367 INDIA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE,
2024–2031 (USD MILLION) 360
TABLE 368 INDIA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 360
TABLE 369 INDIA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 361
TABLE 370 INDIA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION) 361
TABLE 371 INDIA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 362
TABLE 372 INDIA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 362
TABLE 373 INDIA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 363
TABLE 374 INDIA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 363
TABLE 375 INDIA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 364
TABLE 376 INDIA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 364
TABLE 377 INDIA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 364
TABLE 378 INDIA: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 365
TABLE 379 INDIA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 365
TABLE 380 SOUTH KOREA: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 366
TABLE 381 SOUTH KOREA: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 367
TABLE 382 SOUTH KOREA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 367
TABLE 383 SOUTH KOREA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN,
BY TYPE, 2024–2031 (USD MILLION) 368
TABLE 384 SOUTH KOREA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION,
BY TYPE, 2024–2031 (USD MILLION) 368
TABLE 385 SOUTH KOREA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 369
TABLE 386 SOUTH KOREA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 369
TABLE 387 SOUTH KOREA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL,
2024–2031 (USD MILLION) 370
TABLE 388 SOUTH KOREA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 370
TABLE 389 SOUTH KOREA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 371
TABLE 390 SOUTH KOREA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 371
TABLE 391 SOUTH KOREA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 372
TABLE 392 SOUTH KOREA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 372
TABLE 393 SOUTH KOREA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 373
TABLE 394 SOUTH KOREA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 373
TABLE 395 SOUTH KOREA: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 373
TABLE 396 SOUTH KOREA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 374
TABLE 397 AUSTRALIA: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 375
TABLE 398 AUSTRALIA: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 375
TABLE 399 AUSTRALIA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 376
TABLE 400 AUSTRALIA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN,
BY TYPE, 2024–2031 (USD MILLION) 376
TABLE 401 AUSTRALIA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION) 377
TABLE 402 AUSTRALIA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 377
TABLE 403 AUSTRALIA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 378
TABLE 404 AUSTRALIA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL,
2024–2031 (USD MILLION) 378
TABLE 405 AUSTRALIA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 379
TABLE 406 AUSTRALIA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 379
TABLE 407 AUSTRALIA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 380
TABLE 408 AUSTRALIA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 380
TABLE 409 AUSTRALIA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 381
TABLE 410 AUSTRALIA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 381
TABLE 411 AUSTRALIA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 381
TABLE 412 AUSTRALIA: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 382
TABLE 413 AUSTRALIA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 382
TABLE 414 REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 383
TABLE 415 REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 384
TABLE 416 REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 384
TABLE 417 REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 385
TABLE 418 REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION) 385
TABLE 419 REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 386
TABLE 420 REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 386
TABLE 421 REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY AI TOOL,
2024–2031 (USD MILLION) 387
TABLE 422 REST OF ASIA PACIFIC: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 387
TABLE 423 REST OF ASIA PACIFIC: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 388
TABLE 424 REST OF ASIA PACIFIC: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 388
TABLE 425 REST OF ASIA PACIFIC: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 389
TABLE 426 REST OF ASIA PACIFIC: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 389
TABLE 427 REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 390
TABLE 428 REST OF ASIA PACIFIC: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 390
TABLE 429 REST OF ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 390
TABLE 430 REST OF ASIA PACIFIC: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 391
TABLE 431 LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 392
TABLE 432 LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 393
TABLE 433 LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 393
TABLE 434 LATIN AMERICA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 394
TABLE 435 LATIN AMERICA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN,
BY TYPE, 2024–2031 (USD MILLION) 394
TABLE 436 LATIN AMERICA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION) 395
TABLE 437 LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 395
TABLE 438 LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 396
TABLE 439 LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL,
2024–2031 (USD MILLION) 396
TABLE 440 LATIN AMERICA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 397
TABLE 441 LATIN AMERICA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 397
TABLE 442 LATIN AMERICA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 398
TABLE 443 LATIN AMERICA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 398
TABLE 444 LATIN AMERICA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 399
TABLE 445 LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 399
TABLE 446 LATIN AMERICA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 399
TABLE 447 LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 400
TABLE 448 LATIN AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 400
TABLE 449 BRAZIL: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 401
TABLE 450 BRAZIL: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 401
TABLE 451 BRAZIL: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 402
TABLE 452 BRAZIL: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 402
TABLE 453 BRAZIL: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION) 403
TABLE 454 BRAZIL: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 403
TABLE 455 BRAZIL: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 404
TABLE 456 BRAZIL: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION) 404
TABLE 457 BRAZIL: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 405
TABLE 458 BRAZIL: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 405
TABLE 459 BRAZIL: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 406
TABLE 460 BRAZIL: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 406
TABLE 461 BRAZIL: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 406
TABLE 462 BRAZIL: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 407
TABLE 463 BRAZIL: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 407
TABLE 464 BRAZIL: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 407
TABLE 465 BRAZIL: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 408
TABLE 466 MEXICO: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 409
TABLE 467 MEXICO: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 409
TABLE 468 MEXICO: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES,
BY TYPE, 2024–2031 (USD MILLION) 410
TABLE 469 MEXICO: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 410
TABLE 470 MEXICO: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION) 411
TABLE 471 MEXICO: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 411
TABLE 472 MEXICO: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 412
TABLE 473 MEXICO: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION) 412
TABLE 474 MEXICO: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 413
TABLE 475 MEXICO: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 413
TABLE 476 MEXICO: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 414
TABLE 477 MEXICO: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 414
TABLE 478 MEXICO: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 414
TABLE 479 MEXICO: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 415
TABLE 480 MEXICO: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 415
TABLE 481 MEXICO: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 415
TABLE 482 MEXICO: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 416
TABLE 483 REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 417
TABLE 484 REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 417
TABLE 485 REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 418
TABLE 486 REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 418
TABLE 487 REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION) 419
TABLE 488 REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 419
TABLE 489 REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION) 420
TABLE 490 REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL,
2024–2031 (USD MILLION) 420
TABLE 491 REST OF LATIN AMERICA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 421
TABLE 492 REST OF LATIN AMERICA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 421
TABLE 493 REST OF LATIN AMERICA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 422
TABLE 494 REST OF LATIN AMERICA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 422
TABLE 495 REST OF LATIN AMERICA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 423
TABLE 496 REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION) 423
TABLE 497 REST OF LATIN AMERICA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 423
TABLE 498 REST OF LATIN AMERICA: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 424
TABLE 499 REST OF LATIN AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 424
TABLE 500 MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 426
TABLE 501 MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 426
TABLE 502 MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 427
TABLE 503 MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 427
TABLE 504 MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 428
TABLE 505 MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION) 428
TABLE 506 MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 429
TABLE 507 MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE, 2024–2031 (USD MILLION) 429
TABLE 508 MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL,
2024–2031 (USD MILLION) 430
TABLE 509 MIDDLE EAST & AFRICA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 430
TABLE 510 MIDDLE EAST & AFRICA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 431
TABLE 511 MIDDLE EAST & AFRICA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 431
TABLE 512 MIDDLE EAST & AFRICA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 432
TABLE 513 MIDDLE EAST & AFRICA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 432
TABLE 514 MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT, 2024–2031 (USD MILLION) 432
TABLE 515 MIDDLE EAST & AFRICA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 433
TABLE 516 MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 433
TABLE 517 MIDDLE EAST & AFRICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 433
TABLE 518 GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 434
TABLE 519 GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 435
TABLE 520 GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 435
TABLE 521 GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 436
TABLE 522 GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 436
TABLE 523 GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION,
BY TYPE, 2024–2031 (USD MILLION) 437
TABLE 524 GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 437
TABLE 525 GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 438
TABLE 526 GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET, BY AI TOOL,
2024–2031 (USD MILLION) 438
TABLE 527 GCC COUNTRIES: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 439
TABLE 528 GCC COUNTRIES: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 439
TABLE 529 GCC COUNTRIES: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 440
TABLE 530 GCC COUNTRIES: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 440
TABLE 531 GCC COUNTRIES: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 440
TABLE 532 GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 441
TABLE 533 GCC COUNTRIES: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 441
TABLE 534 GCC COUNTRIES: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 441
TABLE 535 GCC COUNTRIES: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 442
TABLE 536 SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 443
TABLE 537 SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 443
TABLE 538 SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 444
TABLE 539 SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN,
BY TYPE, 2024–2031 (USD MILLION) 444
TABLE 540 SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION,
BY TYPE, 2024–2031 (USD MILLION) 445
TABLE 541 SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 445
TABLE 542 SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 446
TABLE 543 SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL,
2024–2031 (USD MILLION) 446
TABLE 544 SAUDI ARABIA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 447
TABLE 545 SAUDI ARABIA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 447
TABLE 546 SAUDI ARABIA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 448
TABLE 547 SAUDI ARABIA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 448
TABLE 548 SAUDI ARABIA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 449
TABLE 549 SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 449
TABLE 550 SAUDI ARABIA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 449
TABLE 551 SAUDI ARABIA: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 450
TABLE 552 SAUDI ARABIA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 450
TABLE 553 UAE: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION) 451
TABLE 554 UAE: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION) 452
TABLE 555 UAE: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 452
TABLE 556 UAE: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 453
TABLE 557 UAE: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE,
2024–2031 (USD MILLION) 453
TABLE 558 UAE: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 454
TABLE 559 UAE: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 454
TABLE 560 UAE: AI IN DRUG DISCOVERY MARKET, BY AI TOOL, 2024–2031 (USD MILLION) 455
TABLE 561 UAE: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 455
TABLE 562 UAE: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 456
TABLE 563 UAE: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 456
TABLE 564 UAE: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 457
TABLE 565 UAE: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 457
TABLE 566 UAE: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 457
TABLE 567 UAE: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 458
TABLE 568 UAE: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION) 458
TABLE 569 UAE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 458
TABLE 570 REST OF GCC: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 459
TABLE 571 REST OF GCC: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 460
TABLE 572 REST OF GCC: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 460
TABLE 573 REST OF GCC: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN,
BY TYPE, 2024–2031 (USD MILLION) 461
TABLE 574 REST OF GCC: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION,
BY TYPE, 2024–2031 (USD MILLION) 461
TABLE 575 REST OF GCC: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 462
TABLE 576 REST OF GCC: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 462
TABLE 577 REST OF GCC: AI IN DRUG DISCOVERY MARKET, BY AI TOOL,
2024–2031 (USD MILLION) 463
TABLE 578 REST OF GCC: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 463
TABLE 579 REST OF GCC: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 464
TABLE 580 REST OF GCC: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 464
TABLE 581 REST OF GCC: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 465
TABLE 582 REST OF GCC: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 465
TABLE 583 REST OF GCC: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 465
TABLE 584 REST OF GCC: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 466
TABLE 585 REST OF GCC: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 466
TABLE 586 REST OF GCC: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI
IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 466
TABLE 587 SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET, BY PROCESS,
2024–2031 (USD MILLION) 467
TABLE 588 SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET, BY USE CASE,
2024–2031 (USD MILLION) 468
TABLE 589 SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 468
TABLE 590 SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET FOR DE NOVO DRUG DESIGN,
BY TYPE, 2024–2031 (USD MILLION) 469
TABLE 591 SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION,
BY TYPE, 2024–2031 (USD MILLION) 469
TABLE 592 SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 470
TABLE 593 SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET, BY PLAYER TYPE,
2024–2031 (USD MILLION) 470
TABLE 594 SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET, BY AI TOOL,
2024–2031 (USD MILLION) 471
TABLE 595 SOUTH AFRICA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 471
TABLE 596 SOUTH AFRICA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 472
TABLE 597 SOUTH AFRICA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 472
TABLE 598 SOUTH AFRICA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 473
TABLE 599 SOUTH AFRICA: AGENTIC AI & CO-SCIENTISTS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 473
TABLE 600 SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET, BY DEPLOYMENT,
2024–2031 (USD MILLION) 473
TABLE 601 SOUTH AFRICA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET,
BY TYPE, 2024–2031 (USD MILLION) 474
TABLE 602 SOUTH AFRICA: AI IN DRUG DISCOVERY MARKET, BY END USER,
2024–2031 (USD MILLION) 474
TABLE 603 SOUTH AFRICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI
IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 474
TABLE 604 REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY PROCESS, 2024–2031 (USD MILLION) 476
TABLE 605 REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2024–2031 (USD MILLION) 476
TABLE 606 REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASES, BY TYPE, 2024–2031 (USD MILLION) 477
TABLE 607 REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET FOR
DE NOVO DRUG DESIGN, BY TYPE, 2024–2031 (USD MILLION) 477
TABLE 608 REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET FOR DRUG OPTIMIZATION, BY TYPE, 2024–2031 (USD MILLION) 478
TABLE 609 REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET,
BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 478
TABLE 610 REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET,
BY PLAYER TYPE, 2024–2031 (USD MILLION) 479
TABLE 611 REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET,
BY AI TOOL, 2024–2031 (USD MILLION) 479
TABLE 612 REST OF MIDDLE EAST & AFRICA: MACHINE LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 480
TABLE 613 REST OF MIDDLE EAST & AFRICA: DEEP LEARNING IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 480
TABLE 614 REST OF MIDDLE EAST & AFRICA: GENERATIVE AI IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 481
TABLE 615 REST OF MIDDLE EAST & AFRICA: FOUNDATION MODELS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 481
TABLE 616 REST OF MIDDLE EAST & AFRICA: AGENTIC AI & CO-SCIENTISTS IN AI
IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 481
TABLE 617 REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET,
BY DEPLOYMENT, 2024–2031 (USD MILLION) 482
TABLE 618 REST OF MIDDLE EAST & AFRICA: CLOUD-BASED SOLUTIONS IN AI IN DRUG DISCOVERY MARKET, BY TYPE, 2024–2031 (USD MILLION) 482
TABLE 619 REST OF MIDDLE EAST & AFRICA: AI IN DRUG DISCOVERY MARKET, BY END USER, 2024–2031 (USD MILLION) 482
TABLE 620 REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN AI IN DRUG DISCOVERY MARKET, BY TYPE,
2024–2031 (USD MILLION) 483
TABLE 621 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN DRUG DISCOVERY MARKET, JANUARY 2023–JUNE 2026 485
TABLE 622 AI IN DRUG DISCOVERY MARKET: DEGREE OF COMPETITION 490
TABLE 623 AI IN DRUG DISCOVERY MARKET: REGION FOOTPRINT 496
TABLE 624 AI IN DRUG DISCOVERY MARKET: USE CASE FOOTPRINT 497
TABLE 625 AI IN DRUG DISCOVERY MARKET: PROCESS FOOTPRINT 498
TABLE 626 AI IN DRUG DISCOVERY MARKET: THERAPEUTIC AREA FOOTPRINT 499
TABLE 627 AI IN DRUG DISCOVERY MARKET: PLAYER TYPE FOOTPRINT 500
TABLE 628 AI IN DRUG DISCOVERY MARKET: DEPLOYMENT FOOTPRINT 501
TABLE 629 AI IN DRUG DISCOVERY MARKET: DETAILED LIST OF KEY STARTUPS/SMES 504
TABLE 630 AI IN DRUG DISCOVERY MARKET: REGION FOOTPRINT (STARTUPS/SMES) 504
TABLE 631 AI IN DRUG DISCOVERY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY PROCESS 505
TABLE 632 AI IN DRUG DISCOVERY MARKET: PRODUCT/SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 505
TABLE 633 AI IN DRUG DISCOVERY MARKET: DEALS, JANUARY 2023–JULY 2026 506
TABLE 634 AI IN DRUG DISCOVERY MARKET: EXPANSIONS, JANUARY 2023–JULY 2026 507
TABLE 635 AI IN DRUG DISCOVERY MARKET: OTHER DEVELOPMENTS,
JANUARY 2023–JULY 2026 507
TABLE 636 NVIDIA CORPORATION: COMPANY OVERVIEW 508
TABLE 637 NVIDIA CORPORATION: PRODUCTS/SERVICES OFFERED 510
TABLE 638 NVIDIA CORPORATION: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026 511
TABLE 639 NVIDIA CORPORATION: DEALS, JANUARY 2023–JULY 2026 512
TABLE 640 NVIDIA: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 515
TABLE 641 ALPHABET INC.: COMPANY OVERVIEW 517
TABLE 642 ALPHABET, INC: PRODUCTS/SERVICES OFFERED 518
TABLE 643 ALPHABET INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026 519
TABLE 644 ALPHABET INC.: DEALS, JANUARY 2023–JULY 2026 520
TABLE 645 ALPHABET, INC.: DEALS, JANUARY 2023–JULY 2026 521
TABLE 646 RECURSION: COMPANY OVERVIEW 522
TABLE 647 RECURSION: PRODUCTS/SERVICES OFFERED 523
TABLE 648 RECURSION: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026 524
TABLE 649 RECURSION: DEALS, JANUARY 2023–JULY 2026 524
TABLE 650 RECURSION: EXPANSION, JANUARY 2023–JULY 2026 526
TABLE 651 INSILICO MEDICINE: COMPANY OVERVIEW 528
TABLE 652 INSILICO MEDICINE: PRODUCTS /SERVICES OFFERED 529
TABLE 653 INSILICO MEDICINE: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026 530
TABLE 654 INSILICO MEDICINE: DEALS, JANUARY 2023–JULY 2026 531
TABLE 655 INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 534
TABLE 656 INSILICO MEDICINE: EXPANSIONS, JANUARY 2023–JULY 2026 534
TABLE 657 SCHRÖDINGER, INC.: COMPANY OVERVIEW 536
TABLE 658 SCHRÖDINGER, INC.: PRODUCTS/SERVICES OFFERED 537
TABLE 659 SCHRÖDINGER, INC.: DEALS, JANUARY 2023–JULY 2026 538
TABLE 660 SCHRÖDINGER, INC.: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 539
TABLE 661 BENEVOLENTAI: COMPANY OVERVIEW 541
TABLE 662 BENEVOLENTAI: PRODUCTS/ SERVICES OFFERED 542
TABLE 663 BENEVOLENTAI: DEALS, JANUARY 2023–JULY 2026 542
TABLE 664 MICROSOFT CORPORATION: COMPANY OVERVIEW 544
TABLE 665 MICROSOFT CORPORATION: PRODUCTS /SERVICES OFFERED 545
TABLE 666 MICROSOFT CORPORATION: PRODUCT/SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 546
TABLE 667 MICROSOFT CORPORATION: DEALS, JANUARY 2023–JULY 2026 546
TABLE 668 NUMERION LABS: COMPANY OVERVIEW 548
TABLE 669 NUMERION LABS: PRODUCTS/SERVICES OFFERED 549
TABLE 670 ILLUMINA, INC.: COMPANY OVERVIEW 550
TABLE 671 ILLUMINA, INC.: PRODUCTS/SERVICES OFFERED 551
TABLE 672 ILLUMINA, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026 553
TABLE 673 ILLUMINA, INC.: DEALS, JANUARY 2023–JULY 2026 554
TABLE 674 XTALPI INC.: COMPANY OVERVIEW 556
TABLE 675 XTALPI INC.: PRODUCTS/SERVICES OFFERED 557
TABLE 676 XTALPI INC.: DEALS, JANUARY 2023–JULY 2026 558
TABLE 677 IKTOS: COMPANY OVERVIEW 560
TABLE 678 IKTOS: PRODUCTS/SERVICES OFFERED 561
TABLE 679 IKTOS: DEALS, JANUARY 2023–JULY 2026 562
TABLE 680 IKTOS: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 563
TABLE 681 TEMPUS AI, INC.: COMPANY OVERVIEW 564
TABLE 682 TEMPUS AI, INC.: PRODUCTS/SERVICES OFFERED 565
TABLE 683 TEMPUS AI, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026 566
TABLE 684 TEMPUS AI, INC.: DEALS, JANUARY 2023–JULY 2026 567
TABLE 685 DEEP GENOMICS, INC.: COMPANY OVERVIEW 570
TABLE 686 DEEP GENOMICS, INC.: PRODUCTS/SERVICES OFFERED 570
TABLE 687 DEEP GENOMICS, INC.: PRODUCT/SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 571
TABLE 688 VERGE LABS: COMPANY OVERVIEW 572
TABLE 689 VERGE LABS: PRODUCTS/SERVICES OFFERED 573
TABLE 690 VERGE GENOMICS: DEALS, JANUARY 2023–JULY 2026 573
TABLE 691 BENCHSCI: COMPANY OVERVIEW 575
TABLE 692 BENCHSCI: PRODUCTS/SERVICES OFFERED 575
TABLE 693 BENCHSCI: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026 576
TABLE 694 BENCHSCI: DEALS, JANUARY 2023–JULY 2026 576
TABLE 695 BENCHSCI: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 577
TABLE 696 INSITRO: COMPANY OVERVIEW 578
TABLE 697 INSITRO: PRODUCTS/SERVICES OFFERED 578
TABLE 698 INSITRO: DEALS, JANUARY 2023–JULY 2026 579
TABLE 699 INSITRO: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 579
TABLE 700 VALO HEALTH: COMPANY OVERVIEW 580
TABLE 701 VALO HEALTH: PRODUCTS/SERVICES OFFERED 580
TABLE 702 VALO HEALTH: DEALS, JANUARY 2023–JULY 2026 581
TABLE 703 VALO HEALTH: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 582
TABLE 704 BPGBIO, INC.: COMPANY OVERVIEW 583
TABLE 705 BPGBIO, INC.: PRODUCTS/SERVICES OFFERED 583
TABLE 706 BPGBIO, INC.: DEALS, JANUARY 2023–JULY 2026 584
TABLE 707 GENERATE:BIOMEDICINES: COMPANY OVERVIEW 585
TABLE 708 GENERATE:BIOMEDICINES: PRODUCTS/SERVICES OFFERED 585
TABLE 709 GENERATE:BIOMEDICINES: PRODUCT/SERVICE LAUNCHES,
JANUARY 2023–JULY 2026 586
TABLE 710 GENERATE:BIOMEDICINES: DEALS, JANUARY 2023–JULY 2026 587
TABLE 711 GENERATE:BIOMEDICINES: EXPANSIONS, JANUARY 2023–JULY 2026 588
TABLE 712 CERTARA, INC.: COMPANY OVERVIEW 589
TABLE 713 CERTARA, INC.: PRODUCTS/SERVICES OFFERED 590
TABLE 714 CERTARA, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2023–JULY 2026 591
TABLE 715 CERTARA, INC.: DEALS, JANUARY 2023–JULY 2026 592
TABLE 716 RISK ASSESSMENT: AI IN DRUG DISCOVERY MARKET 614
FIGURE 1 AI IN DRUG DISCOVERY MARKET SEGMENTATION 50
FIGURE 2 REGIONAL SCOPE 51
FIGURE 3 MARKET SCENARIO 58
FIGURE 4 GLOBAL AI IN DRUG DISCOVERY MARKET, 2024–2031 58
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN DRUG DISCOVERY MARKET, 2023–2026 59
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF AI IN DRUG DISCOVERY MARKET 60
FIGURE 7 HIGH-GROWTH SEGMENTS IN AI IN DRUG DISCOVERY MARKET, 2026–2031 61
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN AI IN DRUG DISCOVERY MARKET DURING FORECAST PERIOD 62
FIGURE 9 RISING DEMAND FOR AI IN DRUG DISCOVERY AND REDUCED DRUG DEVELOPMENT COSTS TO DRIVE MARKET GROWTH 64
FIGURE 10 CLOUD-BASED SOLUTIONS AND US ACCOUNTED FOR LARGEST MARKET SHARE
IN NORTH AMERICA IN 2025 65
FIGURE 11 JAPAN TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 66
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN ENVIRONMENTAL MONITORING MARKET 68
FIGURE 13 APPROVAL OF PERSONALIZED MEDICINES BY US FDA, 2020–2024 78
FIGURE 14 AI IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 84
FIGURE 15 AI IN DRUG DISCOVERY MARKET: VALUE CHAIN ANALYSIS 89
FIGURE 16 AI IN DRUG DISCOVERY MARKET: ECOSYSTEM ANALYSIS 91
FIGURE 17 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 97
FIGURE 19 PATENT PUBLICATION TRENDS IN AI IN DRUG DISCOVERY MARKET, 2015–2026 109
FIGURE 20 JURISDICTION AND TOP APPLICANT ANALYSIS FOR AI IN DRUG
DISCOVERY MARKET 109
FIGURE 21 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR AI IN DRUG DISCOVERY MARKET (JANUARY 2015 TO AUGUST 2026) 110
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 130
FIGURE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS 131
FIGURE 24 NORTH AMERICA: AI IN DRUG DISCOVERY MARKET SNAPSHOT 239
FIGURE 25 ASIA PACIFIC: AI IN DRUG DISCOVERY MARKET SNAPSHOT 331
FIGURE 26 AI IN DRUG DISCOVERY MARKET: REVENUE ANALYSIS OF KEY PLAYERS 488
FIGURE 27 AI IN DRUG DISCOVERY MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 489
FIGURE 28 AI IN DRUG DISCOVERY MARKET: BRAND COMPARATIVE ANALYSIS 491
FIGURE 29 EV/EBITDA OF KEY VENDORS 492
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 492
FIGURE 31 AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX,
KEY PLAYERS (2025) 494
FIGURE 32 AI IN DRUG DISCOVERY MARKET: COMPANY FOOTPRINT 495
FIGURE 33 AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 503
FIGURE 34 NVIDIA CORPORATION: COMPANY SNAPSHOT (2026) 509
FIGURE 35 ALPHABET INC.: COMPANY SNAPSHOT (2025) 518
FIGURE 36 RECURSION: COMPANY SNAPSHOT (2025) 523
FIGURE 37 INSILICO MEDICINE: COMPANY SNAPSHOT (2025) 529
FIGURE 38 SCHRÖDINGER, INC.: COMPANY SNAPSHOT (2025) 537
FIGURE 39 MICROSOFT CORPORATION: COMPANY SNAPSHOT (2026) 545
FIGURE 40 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 551
FIGURE 41 XTALPI INC.: COMPANY SNAPSHOT (2025) 557
FIGURE 42 TEMPUS AI, INC.: COMPANY SNAPSHOT (2025) 565
FIGURE 43 CERTARA, INC.: COMPANY SNAPSHOT (2025) 590
FIGURE 44 RESEARCH DESIGN 599
FIGURE 45 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 603
FIGURE 46 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 605
FIGURE 47 BOTTOM-UP APPROACH 606
FIGURE 48 TOP-DOWN APPROACH 607
FIGURE 49 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF AI IN DRUG DISCOVERY INDUSTRY 608
FIGURE 50 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 609
FIGURE 51 DATA TRIANGULATION METHODOLOGY 612
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們